Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: The experience of the Oklahoma Registry, 1989 through 2006

Transfusion

Volumn 48, Issue 2, 2008, Pages 349-357

  Nguyen, Loan ^b   Li, Xiaoning ^b   Duvall, Deanna ^b   Terrell, Deirdra R ^b   Vesely, Sara K ^b   George, James N ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; EXPERIENCE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; PATIENT; PLASMAPHERESIS; REGISTER; ROCKY MOUNTAIN SPOTTED FEVER; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; TIME FACTORS;

EID: 38349159575     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01530.x     Document Type: Article

References (19)

1. Taft EG. Thrombotic thrombocytopenic purpura and dose of plasma exchange. Blood 1979 54 : 842 9.
2. Frankel AE, Rubenstein MD, Wall RT. Thrombotic thrombocytopenia purpura: prolonged coma with recovery of neurologic function with intensive plasma exchange. Am J Hematol 1981 10 : 387 90.
3. Kahwash E, Lockwood WB. Twice daily plasma exchange in refractory thrombotic thrombocytopenic purpura. Ther Apher Dial 2004 8 : 254 7.
4. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006 125 : 592 7.
5. Ruggenenti P, Galbusera M, Cornejo RP, Bellavita P, Remuzzi G. Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993 3 : 314 8.
6. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Narr RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991 325 : 393 7.
7. Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, Veyradier A, Leblanc T, Alberti C, Azoulay E, Le Gall JR, Schlemmer B. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine 2003 82 : 27 38.
8. Bandarenko N, Brecher ME Members of the US TTP ASG. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998 13 : 133 41.
9. Allford S, Hunt BJ, Rose P, Machin S Haemostasis and Thrombosis Task Force. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemias. Br J Haematol 2003 120 : 556 73.
10. Brecher ME. How I approach a thrombotic thrombocytopenia purpura patient. Transfusion 2006 46 : 687 9.
11. Vesely SK, George JN, Lammle B, Studt J-D, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 101 : 60 8.
12. George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004 41 : 60 7.
13. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 : 1578 84.
14. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002 100 : 710 3.
15. Hay SN, Egan JA, Millward PA, Bandarenko N, Brecher ME. Patterns of platelet response in idiopathic TTP/HUS: frequency of declining platelet counts with plasma exchange and the recognition and significance of a pseudo refractory state. Ther Apher Dial 2006 10 : 237 41.
16. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004 103 : 4043 9.
17. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Prognostic value of inhibitory anti-ADMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2005 132 : 66 74.
18. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006 21 : 49 56.
19. Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EC, George JN, Wu HM. An evaluation of ciclosporine and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007 132 : 146 9.